CHICAGO -- Mifepristone (Korlym) reduced HbA1c levels in patients with inadequately controlled type 2 diabetes and ...

US biopharma Vertex Pharmaceuticals and Japanese drugmaker Ono Pharmaceutical have announced an exclusive collaboration and ...

US drugmaker Vertex Pharmaceuticals has announced simultaneous presentation and publication of updated data from the Phase ...

While BMO Capital Markets said that zimislecel is “highly encouraging” for type 1 diabetes, questions regarding its target ...

The safety profile of the therapy was found to be favourable, without any serious adverse events linked to the treatment.

"This edition of the Healthcare Enforcement column discusses two judicial decisions from recent months relating to the ...

With this reimbursement, approximately 45 people with cystic fibrosis in Australia will become eligible for a CFTR modulator for the first time –– ...

In phase 2 of the FORWARD study, 83% of participants with type 1 diabetes achieved insulin independence a year after receiving zimislecel (formerly VX-880), an islet cell therapy developed ...

Vertex Pharmaceuticals locked arms with Ono Pharmaceutical in an exclusive deal to advance povetacicept, targeting B ...

OSAKA, Japan & BOSTON, MA, USA I June 23, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) and ...

As of 2021, 1.7 million adults in the United States were living with type 1 diabetes, according to statistics from the CDC.